Aratana Therapeutics, Inc. (NASDAQ:PETX) insider Ernst Heinen sold 10,000 shares of the company’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $6.25, for a total transaction of $62,500.00. Following the sale, the insider now directly owns 130,994 shares in the company, valued at approximately $818,712.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) opened at 5.88 on Friday. The firm’s 50-day moving average is $5.87 and its 200-day moving average is $6.17. Aratana Therapeutics, Inc. has a 12 month low of $4.97 and a 12 month high of $10.73. The company’s market cap is $252.85 million.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 51.21%. The firm had revenue of $5.16 million for the quarter, compared to analysts’ expectations of $4.50 million. During the same quarter in the previous year, the company earned $0.61 earnings per share. The company’s revenue for the quarter was down 86.4% compared to the same quarter last year. On average, equities research analysts predict that Aratana Therapeutics, Inc. will post ($1.09) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/22/insider-selling-aratana-therapeutics-inc-petx-insider-sells-62500-00-in-stock.html.

Several hedge funds have recently added to or reduced their stakes in the business. Ray Gerald L & Associates Ltd. increased its position in shares of Aratana Therapeutics by 0.8% in the second quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock valued at $174,000 after acquiring an additional 200 shares during the period. Janney Montgomery Scott LLC increased its position in shares of Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 1,200 shares during the period. American International Group Inc. increased its position in shares of Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,354 shares during the period. ProShare Advisors LLC increased its position in shares of Aratana Therapeutics by 7.2% in the second quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock valued at $183,000 after acquiring an additional 1,709 shares during the period. Finally, Parametric Portfolio Associates LLC increased its position in shares of Aratana Therapeutics by 6.6% in the second quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 1,875 shares during the period. Hedge funds and other institutional investors own 73.04% of the company’s stock.

A number of analysts have commented on the stock. Jefferies Group LLC set a $8.00 price target on shares of Aratana Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 8th. Zacks Investment Research raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Tuesday, July 4th. ValuEngine cut shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. BidaskClub cut shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Lake Street Capital cut their price target on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Aratana Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.25.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.